Enanta Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.
- Conditions
- Chronic Hepatitis B Virus Infection
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 26
- Registration Number
- NCT04971512
- Locations
- 🇳🇿
New Zealand Clinical Research Ltd, Auckland, New Zealand
Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 8
- Registration Number
- NCT04927793
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT04871724
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc.,, Salt Lake City, Utah, United States
A Study to Evaluate EDP 938 Regimens in Children With RSV
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 96
- Registration Number
- NCT04816721
- Locations
- 🇺🇸
Memorial Care Miller Children's and Women's Hospital, Long Beach, California, United States
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸UC Davis, Sacramento, California, United States
Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects
- Conditions
- Hepatitis B
- Interventions
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT04783753
- Locations
- 🇺🇸
Pharmaceutical Research Association, Lenexa, Kansas, United States
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 9
- Registration Number
- NCT04633187
- Locations
- 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇦🇷Fundación Favaloro, Buenos Aires, Ciudad Autónoma De BuenosAires, Argentina
🇦🇷Instituto Fides, La Plata, Ciudad Autónoma De BuenosAires, Argentina
A Study of EDP-297 in Healthy Subjects
- Conditions
- NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 82
- Registration Number
- NCT04559126
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
- Conditions
- RSV Infection
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 89
- Registration Number
- NCT04498741
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT04470388
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
🇨🇳Changhua Christian Hospital, Changhua, Taiwan
🇨🇳Chia-Yi Christian Hospital, Chiayi, Taiwan
A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH
- Conditions
- Non-Alcoholic Steatohepatitis
- Interventions
- Drug: EDP-305 2 mgDrug: PlaceboDrug: EDP-305 1.5 mg
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 98
- Registration Number
- NCT04378010
- Locations
- 🇺🇸
Arizona Liver Health, Chandler, Arizona, United States
🇺🇸The Institute of Liver Health, Glendale, Arizona, United States
🇺🇸Dignity Health DBA St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States